Потенциал клеточной терапии в лечении унивентрикулярных пороков сердца

Единственный желудочек сердца – группа врожденных пороков, которая и на сегодняшний день остается наиболее тяжелой для хирургического лечения и для дальнейшего ведения пациента. Выживаемость пациентов с данным пороком остается относительно невысокой несмотря на проведение ряда этапных оперативных вмешательств. Большой процент смертности наблюдается в межэтапный период ввиду развития сердечной недостаточности, лечение которой является актуальной проблемой, так как стандартная терапия не оправдывает ожидания. В данной статье выполнен обзор мировой литературы о применении инновационного метода коррекции сердечной недостаточности – клеточной терапии. Также рассмотрены основные виды стволовых клеток, источники их получения, механизм действия и методы доставки к миокарду.

1. Meller C. H., Grinenco S., Aiello H. et al. Congenital heart disease, prenatal diagnosis and management. Arch Argent Pediatr. 2020;118(2):e149‒e161.

2. Bilewska A., Mishra R., Stefanowicz A. et al. Stem cell therapy for single ventricle congenital heart disease ‒ current state and future directions. Postepy w Kardiologii Interwencyjnej. 2022;18(4):319–325.

3. Williams K., Khan A., Lee Y. S., Hare J. M. et al. Cell-based therapy to boost right ventricular function and cardiovascular performance in hypoplastic left heart syndrome: Current approaches and future directions. Semin Perinatol. 2023;47(3):151725.

4. Garbern J. C., Lee R. T. Heart regeneration: 20 years of progress and renewed optimism. Developmental Cell. 2022;57(4):424–439.

5. Cho J., Lee H., Rah W. et al. From engineered heart tissue to cardiac organoid. Theranostics. 2022;12(6):2758–2772.

6. Charitos I. A., Ballini A., Cantore S. et al. Stem cells: a historical review about biological, religious, and ethical issues. Stem Cells International. 2021;2021):9978837.

7. Steensma D. P., Kyle R.A. James till and ernest mcculloch: hematopoietic stem cell discoverers. Mayo Clinic Proceedings. 2021;96(3):830–831.

8. Brunetti G., Di Benedetto A., Posa F. et al. High expression of TRAIL by osteoblastic differentiated dental pulp stem cells affects myeloma cell viability. Oncol Rep. 2018;39(4):2031–2039.

9. Qiu C., Ge Z., Cui W. et al. Human amniotic epithelial stem cells: A promising seed cell for clinical applications. International Journal of Molecular Sciences. 2020;21(20):1–26.

10. Oh M., Lee J., Kim Y. J. et al. Exosomes derived from human induced pluripotent stem cells ameliorate the aging of skin fibroblasts. Int J Mol Sci. 2018;19(6):1715.

11. Boccellino M., Di Stasio D., Dipalma G. et al. Steroids and growth factors in oral squamous cell carcinoma: useful source of dental-derived stem cells to develop a steroidogenic model in new clinical strategies. European Review for Medical and Pharmacological Sciences. 2019;23:8730–8740.

12. Tonkin D., Yee-Goh A., Katare R. Healing the ischaemic heart: a critical review of stem cell therapies. Reviews in Cardiovascular Medicine. 2023;24(4):122.

13. Peregud-Pogorzelska M., Przybycień K., Baumert B. et al. The effect of intracoronary infusion of autologous bone marrow-derived lineage-negative stem/progenitor cells on remodeling of post-infarcted heart in patient with acute myocardial infarction. Int J Med Sci. 2020;17(8):985–994.

14. Rai V., Gładki M., Dudyńska M. et al. Hypoplastic left heart syndrome [HLHS]: treatment options in present era. Indian Journal of Thoracic and Cardiovascular Surgery. 2019;35(2):196–202.

15. Rychik J., Atz A. M., Celermajer D. S. et al. Evaluation and management of the child and adult with fontan circulation: a scientific statement from the American Heart Association. Circulation. 2019;140(6):E234–E284.

16. Metcalf M. K., Rychik J. Outcomes in Hypoplastic Left Heart Syndrome // Pediatric Clinics of North America. 2020;67(5):945‒962.

17. Roeleveld P. P., Axelrod D. M., Klugman D. et al. Hypoplastic left heart syndrome: From fetus to fontan. Cardiol Young. 2018;28(11):1275–1288.

18. Ramonfaur D., Zhang X., Garza A. P. et al. Hypoplastic left heart syndrome: a review. Cardiology in Review. 2023;31(3):149‒154.

19. Schranz D., Esmaeili A., Akintuerk H. Hypoplastic left heart: Stage-I will be performed interventionally, soon. Pediatric Cardiology. 2021; 42(4):727‒735.

20. Das B. B. Current state of pediatric heart failure. Children. 2018;5(7):88.

21. Garcia A. M., Beatty J. T., Nakano S. J. et al. Heart failure in single right ventricle congenital heart disease: physiological and molecular considerations. Am J Physiol Heart Circ Physiol. 2020;318(4):H947‒H965.

22. Danton M. H. D. Right ventricular remodelling in hypoplastic left heart syndrome following Fontan completion. European Journal of Cardiothoracic Surgery. 2022;61(1):43‒44.

23. Carrillo S. A., Texter K. M., Phelps C. et al. Tricuspid Valve and right ventricular function throughout the hybrid palliation strategy for hypoplastic left heart syndrome and variants. World J Pediatr Congenit Heart Surg. 2021;12(1):9‒16.

24. Tretter J. T., Redington A. N. The forgotten ventricle? The left ventricle in right-sided congenital heart disease. Circ Cardiovasc Imaging. 2018; 11(3):e007410.

25. Files M. D., Arya B. Pathophysiology, adaptation, and imaging of the right ventricle in fontan circulation. American Journal of Physiology ‒ Heart and Circulatory Physiology. 2018;315(6):H1779‒H1788.

26. Reddy S., Handler S. S., Wu S. et al. Proceedings from the 2019 stanford single ventricle scientific summit: Advancing science for single ventricle patients: From discovery to clinical applications. J Am Heart Assoc. 2020;9(7):e015871.

27. Brida M., Diller G. P., Gatzoulis M. A. Systemic Right Ventricle in Adults with Congenital Heart Disease. Circulation. 2018;137(5):508–518.

28. Kajimoto M., Nuri M., Isern N. G. et al. Metabolic response of the immature right ventricle to acute pressure overloading. J Am Heart Assoc. 2018;7(11):e008570.

29. Rako Z.A., Kremer N., Yogeswaran A. et al. Adaptive versus maladaptive right ventricular remodelling. ESC Heart Failure. 2023;10(2):762‒775.

30. Kenny L. A., DeRita F., Nassar M. et al. Transplantation in the single ventricle population. Ann Cardiothorac Surg. 2018;7(1):152‒159.

31. Zwischenberger J. B., Breetz K. A., Ballard-Croft C., Wang D. et al. Failing Fontan cardiovascular support: Review. Journal of Cardiac Surgery. 2022;37(12):5257‒5261.

32. Saiki H., Kuwata S., Iwamoto Y. et al. Fenestration in the Fontan circulation as a strategy for chronic cardioprotection. Heart. 2019; 105(16):1266‒1272.

33. Schäfer M., Younoszai A., Truong U. et al. Influence of aortic stiffness on ventricular function in patients with Fontan circulation. Journal of Thoracic and Cardiovascular Surgery. 2019;157(2):699‒707.

34. Devlin P. J., McCrindle B. W., Kirklin J. K. et al. Intervention for arch obstruction after the Norwood procedure: Prevalence, associated factors, and practice variability. Journal of Thoracic and Cardiovascular Surgery. 2019;157(2):684‒695.e8.

35. Hoffman G. M., Scott J. P., Ghanayem N. S. et al. Identification of Time-Dependent Risks of Hemodynamic States After Stage 1 Norwood Palliation. Annals of Thoracic Surgery. 2020;109(1):155‒162.

36. Garcia A. M., Beatty J. T., Nakano S. J. Heart failure in single right ventricle congenital heart disease: Physiological and molecular considerations. American Journal of Physiology ‒ Heart and Circulatory Physiology. 2020;318(4):H947‒H965.

37. Schütte J. P., Manke M. C., Hemmen K. et al. Platelet-derived MicroRNAs regulate cardiac remodeling after myocardial ischemia. Circ Res. 2023; 132(7):e96‒e113.

38. Belostotskaya G., Hendrikx M., Galagudza M. et al. How to stimulate myocardial regeneration in adult mammalian heart: existing views and new approaches. BioMed Research International. 2020; 2020:7874109.

39. Karpov A.A., Puzanov M. V., Ivkin D. Y. et al. Non-inferiority of microencapsulated mesenchymal stem cells to free cells in cardiac repair after myocardial infarction: A rationale for using paracrine factor(s) instead of cells. Int J Exp Pathol. 2019;100(2):102‒113.

40. Belostotskaya G.B., Nerubatskaya I. V., Galagudza M.M. Two mechanisms of cardiac stem cell-mediated cardiomyogenesis in the adult mammalian heart include formation of colonies and cell-in-cell structures. Oncotarget. 2018;9(75):34159‒34175.

41. Hyun I., Munsie M., Pera M. F. et al. Toward Guidelines for Research on Human Embryo Models Formed from Stem Cells. Stem Cell Reports. 2020;14(2):169–174.

42. Liu G., David B. T., Trawczynski M. et al. Advances in pluripotent stem cells: history, mechanisms, technologies, and applications. Stem Cell Reviews and Reports. 2020;16(1):3–32.

43. Sano S., Sano T., Ishigami S., Ito T. Cardiac stem cell therapy: Does a newborn infant’s heart have infinite potential for stem cell therapy? Journal of Thoracic and Cardiovascular Surgery. 2022;163(1):242–247.

44. Amdani S., Marino B. S., Rossano J. et al. Burden of pediatric heart failure in the United States. J Am Coll Cardiol. 2022;79(19):1917–1928.

45. Burkhart H. M., Qureshi M. Y., Rossano J. W. et al. Autologous stem cell therapy for hypoplastic left heart syndrome: Safety and feasibility of intraoperative intramyocardial injections. Journal of Thoracic and Cardiovascular Surgery. 2019;158(6):1614–1623.

46. Зиновьев Е. В., Юдин В. Е., Асадулаев М. С. и др. Опыт применения стволовых клеток при лечении ожогов кожи. Педиатр. 2018. Т. 9, № 4. С. 12–27.

47. Bui T. V. A., Hwang J. W., Lee J. H. et al. Challenges and limitations of strategies to promote therapeutic potential of human mesenchymal stem cells for cell-based cardiac repair. Korean Circulation Journal. 2021;51(2):97–113.

48. Pittenger M. F., Discher D. E., Péault B. M. et al. Mesenchymal stem cell perspective: cell biology to clinical progress. Regenerative Medicine. 2019;4(1):22.

49. Zhu X., Tang B., Sun Z. Umbilical cord blood transplantation: Still growing and improving. Stem Cells Translational Medicine. 2021;10(S2):S62‒ S74.

50. Nana-Leventaki E., Nana M., Poulianitis N. et al. Cardiosphere-derived cells attenuate inflammation, preserve systolic function, and prevent adverse remodeling in rat hearts with experimental autoimmune myocarditis. J Cardiovasc Pharmacol Ther. 2019;24(1):70–77.

51. Campostrini G., Windt L. M., van Meer B. J. et al. Cardiac tissues from stem cells: new routes to maturation and cardiac regeneration. Circ Res. Lippincott Williams and Wilkins, 2021;128(6):775–801.

52. Kaushal S., Hare J. M., Hoffman J. R. et al. Intramyocardial cell-based therapy with Lomecel-B during bidirectional cavopulmonary anastomosis for hypoplastic left heart syndrome: The ELPIS phase i trial. European Heart Journal Open. 2023;3(2):oead002.

53. Mastrangelo F., Scacco S., Ballini A. et al. A pilot study of human mesenchymal stem cells from visceral and sub-cutaneous fat tissue and their differentiation to osteogenic phenotype. Eur Rev Med Pharmacol Sci. 2019;23(7):2924‒2934.

54. Corno A. F., Findley T. O., Salazar J. D. Narrative review of single ventricle: where are we after 40 years? Translational Pediatrics. 2023; 12(2): 221–244.

55. Wallace E., Howard L., Liu M. et al. Long QT syndrome: genetics and future perspective. Pediatric Cardiology. 2019;40(7):1419–1430.

56. Freud L. R., Seed M. Prenatal diagnosis and management of single-ventricle heart disease. Canadian Journal of Cardiology. 2022; 38(7):897‒908.